A recent report written by the outgoing House Energy & Commerce (E&C) Committee majority staff argues that the FDA “ignored the science “when it approved Aduhelm (a treatment to slow the progression of Alzheimer's Disease). The Democrats claim the developer of the medicine, Biogen, inappropriately conspired with the FDA to cut corners resulting in an approval without clear evidence of effectiveness.
Read Full Article »
